A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Researchers are looking for new ways to treat people with extensive-stage small cell lung cancer (SCLC) that has relapsed or is refractory. Gocatamig is a new type of immunotherapy that uses a person's immune system to find and destroy cancer cells. Ifinatamab deruxtecan (also known as I-DXd) is a drug which binds to a specific target on cancer cells and delivers treatment to destroy those cells. Durvalumab is a different type of immunotherapy that also destroys cancer cells. Researchers want to know if giving gocatamig, I-DXd, and gocatamig with I-DXd or durvalumab can treat SCLC that did not respond or stopped responding to a prior treatment. The goals of this study are to learn: * If gocatamig alone, I-DXd alone, and gocatamig with I-DXd or durvalumab are safe and well tolerated * If people who receive gocatamig alone, I-DXd alone, and gocatamig with I-DXd or durvalumab have their SCLC get smaller or go away
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rak płuca drobnokomórkowy, który rozprzestrzenił się i nie zareagował lub przestał reagować na co najmniej jedno wcześniejsze leczenie.
- •Możliwość dostarczenia próbki guza z poprzedniego leczenia lub świeżej próbki pobranej podczas biopsji.
- •Osoby zakażone wirusem HIV muszą mieć dobrze kontrolowane HIV dzięki leczeniu.
✗ Disqualifies
- •Nagromadzenie płynu w jamie opłucnej, osierdziu lub jamie brzusznej, wymagające częstego drenażu.
- •Choroby płuc, które mogły zaszkodzić płucom (np. zapalenie płuc o podłożu immunologicznym), chyba że były związane z leczeniem promieniowaniem i nie wymagały sterydów.
- •Aktywne lub podejrzenie chorób płuc.
- •Poważne problemy z oddychaniem z powodu innych chorób płuc.
- •Problemy z układem odpornościowym, z wyjątkiem dobrze kontrolowanego HIV.
- •W ciągu ostatnich 6 miesięcy przed rozpoczęciem badania: poważne problemy z sercem lub naczyniami krwionośnymi (np. zawał, udar) lub zabiegi na tętnicach.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 6, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (48)
University of Colorado Anschutz Medical Campus ( Site 1110)
Aurora, United States
University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 1111)
Miami, United States
University of Chicago ( Site 1108)
Chicago, United States
Dana Farber Cancer Institute ( Site 1105)
Boston, United States
John Theurer Cancer Center at Hackensack University Medical Center ( Site 1103)
Hackensack, United States
Roswell Park Cancer Institute ( Site 1107)
Buffalo, United States
Providence Portland Medical Center ( Site 1101)
Portland, United States
Sarah Cannon Research Institute ( Site 7001)
Nashville, United States
Medical College of Wisconsin ( Site 1112)
Milwaukee, United States
Hospital Universitario Austral ( Site 2204)
Pilar, Argentina
Sanatorio Parque ( Site 2203)
Rosario, Argentina
Princess Alexandra Hospital ( Site 5300)
Woolloongabba, Australia
Monash Health ( Site 5301)
Clayton, Australia
FALP ( Site 2100)
Santiago, Chile
Pontificia Universidad Catolica de Chile ( Site 2102)
Santiago, Chile
Bradfordhill ( Site 2101)
Santiago, Chile
Beijing Cancer Hospital ( Site 5401)
Beijing, China
Fujian Cancer Hospital ( Site 5413)
Fuzhou, China
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Oncology ( Site 5403)
Nanjing, China
Shanghai Chest Hospital ( Site 5400)
Shanghai, China
Shanghai Pulmonary Hospital ( Site 5405)
Shanghai, China
West China Hospital of Sichuan University ( Site 5416)
Chengdu, China
The First Affiliated Hospital, Zhejiang University ( Site 5404)
Hangzhou, China
Rambam Health Care Campus ( Site 3202)
Haifa, Israel
Shaare Zedek Medical Center ( Site 3200)
Jerusalem, Israel
Rabin Medical Center ( Site 3203)
Petah Tikva, Israel
Sheba Medical Center ( Site 3201)
Ramat Gan, Israel
Aichi Cancer Center ( Site 5000)
Nagoya, Japan
National Cancer Center Hospital East ( Site 5001)
Kashiwa, Japan
Kansai Medical University Hospital ( Site 5004)
Hirakata, Japan
Cancer Institute Hospital of JFCR ( Site 5002)
Koto, Japan
Seoul National University Hospital ( Site 5100)
Seoul, South Korea
Severance Hospital, Yonsei University Health System ( Site 5102)
Seoul, South Korea
Samsung Medical Center ( Site 5101)
Seoul, South Korea
HOSPITAL CLÍNIC DE BARCELONA ( Site 3310)
Eixample, Spain
Institut Català d'Oncologia - L'Hospitalet ( Site 3317)
L'Hospitalet de Llobregat, Spain
Hospital Clinico San Carlos... ( Site 3316)
Madrid, Spain
Hospital Universitari Vall d'Hebron ( Site 3311)
Barcelona, Spain
Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJD ( Site 3315)
Madrid, Spain
Hospital Universitario HM Sanchinarro ( Site 3313)
Madrid, Spain
Hospital Universitario Virgen de la Victoria ( Site 3312)
Málaga, Spain
National Cheng Kung University Hospital ( Site 5202)
Tainan, Taiwan
Taipei Medical University Hospital ( Site 5201)
Taipei, Taiwan
Hacettepe Universite Hastaneleri ( Site 3410)
Ankara, Turkey (Türkiye)
Ankara Bilkent Sehir Hastanesi ( Site 3412)
Ankara, Turkey (Türkiye)
National Institute for Health Research UCLH Clinical Research Facility ( Site 3902)
London, United Kingdom
The Clatterbridge Cancer Centre ( Site 3903)
Liverpool, United Kingdom
The Christie NHS Foundation Trust ( Site 3901)
Manchester, United Kingdom
Trial contact
Toll Free Number
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/7/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.